Welcome to our dedicated page for Vuzix SEC filings (Ticker: VUZI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to locate Vuzix鈥檚 waveguide patent numbers or defence contract revenue buried in a 300-page filing? Augmented-reality companies like Vuzix pack technical jargon, OEM commitments and R&D milestones into every report, making it tough to spot what moves the stock.
Stock Titan surfaces the answers instantly. Our AI reads each Vuzix quarterly earnings report 10-Q filing, Vuzix annual report 10-K simplified, and every Vuzix 8-K material event explained, then delivers plain-English highlights you can scan in seconds. Need real-time Vuzix Form 4 insider transactions? We alert you the moment executives file, so tracking Vuzix executive stock transactions Form 4 becomes effortless.
- AI-powered summaries that translate optical-physics disclosures into actionable numbers
- AG真人官方-time feed of all SEC submissions鈥�10-K, 10-Q, 8-K, S-1, DEF 14A proxy statements for executive compensation
- Instant search answers to natural questions like 鈥淗ow much did Vuzix spend on R&D last quarter?鈥� or 鈥淪how me Vuzix insider trading Form 4 transactions鈥�
Whether you鈥檙e comparing segment sales, monitoring OEM revenue share or reviewing dilution from at-the-market offerings, our platform keeps every disclosure at your fingertips. Skip the PDF hunt, and start understanding Vuzix SEC documents with AI鈥撵谤辞尘 Vuzix earnings report filing analysis to detailed proxy statement executive compensation data鈥攕o you can make informed decisions faster.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) has filed a Form S-3 shelf registration covering up to 13,160,172 shares of Class A common stock that may be issued upon exercise of a privately placed Series D warrant. The warrant was issued on 20 May 2025 to Armistice Capital in exchange for the cash exercise, at a reduced price of $0.65, of earlier warrants. It is exercisable immediately, expires five years after stockholder approval and, if exercised for cash, would deliver roughly $8.6 million in gross proceeds to the company.
Only the selling stockholder is registering shares; Rani itself will not sell stock under this prospectus and will receive proceeds solely from warrant exercises. Armistice may resell the shares from time to time through various methods, bearing all underwriting costs. A 4.99 % beneficial-ownership cap limits single-time exercises, but the filing still adds a meaningful trading overhang: the registered shares equal about 21 % of Rani鈥檚 63.2 million basic shares outstanding as of 30 June 2025.
Rani remains a clinical-stage drug-delivery company with no approved products and has expressed 鈥渟ubstantial doubt鈥� regarding its ability to continue as a going concern. The company is advancing two oral-biologics capsule platforms (RaniPill GO and high-capacity RaniPill HC, the latter expected to enter the clinic mid-2025). Proceeds from any cash exercises are earmarked, via an internal LLC structure, for working capital and general corporate purposes.
- Last closing price (2 July 2025): $0.53, below the warrant鈥檚 $0.65 strike, so immediate conversion is unlikely without price appreciation.
- Transfer restrictions: Series D warrant is unlisted; the Class A shares trade on Nasdaq.
- The filing reiterates numerous risk factors, including liquidity constraints, reliance on additional capital and successful clinical progress.
Net-net, the S-3 creates potential dilution and trading pressure but also a pathway to modest capital inflow if the share price recovers.
Vuzix Corporation (VUZI) 鈥� Form 4 insider transaction
Director Edward William Kay Jr. filed a Form 4 reporting the acquisition of 31,746 shares of common stock on 1 July 2025. The transaction code 鈥淎鈥� denotes an acquisition and is identified as a stock award that will vest on the one-year anniversary of the grant date. The shares were granted at a stated price of $0, implying no cash outlay by the director.
After the award, Kay鈥檚 direct beneficial ownership stands at 309,511 shares. No derivative securities or share dispositions were disclosed in the filing.
- Insider role: Director
- Ownership form: Direct
- Earliest transaction date: 01 Jul 2025
- Form signed: 03 Jul 2025
The filing reflects routine equity compensation rather than an open-market purchase, but it modestly increases insider equity alignment with other shareholders.
Form 4 filing overview 鈥� Teradyne, Inc. (TER)
On 07/01/2025, director Henry Andrew Chisholm received an equity award of 2,132 restricted stock units (RSUs) under Teradyne鈥檚 2006 Equity and Cash Compensation Incentive Plan. Each RSU represents the right to receive one share of common stock at no purchase cost.
Key terms
- Grant size: 2,132 RSUs
- Acquisition price: $0 (equity compensation, not an open-market purchase)
- Vesting schedule: 100% on the earlier of the 2026 Annual Meeting of Shareholders or the last Thursday in May 2026
- Post-transaction ownership: 2,132 shares held directly
The filing reports no sales, options, or other derivative transactions. This appears to be a routine annual equity grant that aligns the director鈥檚 incentives with shareholder interests and has no immediate cash impact on the company.
Vuzix Corporation held its annual stockholder meeting on June 17, 2025, where shareholders voted on several key matters. The meeting resulted in multiple significant decisions:
- Board Elections: All five directors were re-elected, including Paul Travers, Grant Russell, Edward Kay, Timothy Harned, and Paula Whitten-Doolin
- Capital Structure Change: Shareholders approved increasing authorized common stock to 200 million shares
- Executive Compensation: Stockholders approved the compensation package for named executives and voted for annual advisory votes on executive compensation
- Equity Restructuring: Approved grant of 594,056 RSUs while canceling 5,089,500 previously issued options
- Auditor Appointment: Freed Maxick P.C. ratified as independent public accounting firm for 2025
All proposals received majority approval, with the authorized share increase receiving 39.9 million votes in favor. The RSU grant approval suggests a significant shift in the company's equity compensation structure.
FAQ
What is the current stock price of Vuzix (VUZI)?
What is the market cap of Vuzix (VUZI)?
What is Vuzix's primary business?
How does Vuzix generate revenue?
What distinguishes Vuzix products in the market?
In which industries does Vuzix operate?
How does Vuzix support software and developer ecosystems?
What role does innovation play in Vuzix's strategy?
